Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Most Read from Bloomberg In Cleveland, a Forgotten Streetcar Bridge Gets a Long-Awaited Lift Amtrak Wins $300 Million to Fix Its Unreliable NJ-to-NYC Service A Bug's Eye View of Mexico City's Modernist Architecture NYC Congestion Pricing Plan With $9 Toll to Start in January Zimbabwe City of 700,000 at Risk of Running Dry by Year-End “We feel confident in being able to fund this as a fully cash deal,” Torley said in an interview. “Equity will not be used. As we take on some debt, our strong cash flow will be able to bring us down to two times leverage very rapidly” after the deal closes, she said. Halozyme's stock fell more than 15% Friday after it publicly revealed it had submitted a non-binding proposal to buy Evotec for €11 per share. The drop was partially due to investor concern that the possible deal would be funded with equity and thus dilutive to shareholders. Halozyme, based in San Diego, plans to fund a portion of the offer with some of the roughly $600 mill
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.MarketBeat
- HALO vs. FOLD: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
- Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Cencora, Inc. (COR) This Year? [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 10/31/24 - Beat
HALO
Sec Filings
- 11/12/24 - Form SC
- 10/31/24 - Form 10-Q
- 10/31/24 - Form 8-K
- HALO's page on the SEC website